Poseida Therapeutics, Inc. (PSTX)

Poseida Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	82.5	64.7	130.49	31.24	0	0
Revenue Growth (YoY)	-40.82%	-50.42%	317.73%	-	-	-
Gross Profit	82.5	64.7	130.49	31.24	0	0
Selling, General & Admin	35.43	37.44	37.54	35.92	23.03	18.46
Research & Development	161.64	156.77	152.9	136.73	103.52	60.39
Other Operating Expenses	0	0	0	0	0	6.68
Operating Expenses	197.07	194.21	190.44	172.65	126.55	85.53
Operating Income	-114.56	-129.5	-59.95	-141.41	-126.55	-85.53
Interest Expense / Income	8.9	8.67	6.37	3.36	3.51	3.55
Other Expense / Income	-14.71	-14.85	-2.86	-19.8	-0.28	-2.56
Pretax Income	-108.75	-123.32	-63.46	-124.97	-129.78	-86.53
Income Tax	0.11	0.11	0.54	0	0	0
Net Income	-108.86	-123.43	-64	-124.97	-129.78	-86.53
Shares Outstanding (Basic)	96	90	72	62	36	13
Shares Outstanding (Diluted)	96	90	72	62	36	13
Shares Change	11.31%	25.34%	15.61%	72.89%	185.27%	3.57%
EPS (Basic)	-1.18	-1.37	-0.89	-2.01	-3.61	-6.86
EPS (Diluted)	-1.18	-1.37	-0.89	-2.01	-3.61	-6.86
Free Cash Flow	-71.71	-95.23	-30.68	-105.16	-130.24	-69.67
Free Cash Flow Per Share	-0.75	-1.06	-0.43	-1.69	-3.62	-5.52
Gross Margin	100.00%	100.00%	100.00%	100.00%	-	-
Operating Margin	-138.86%	-200.15%	-45.94%	-452.69%	-	-
Profit Margin	-131.94%	-190.76%	-49.05%	-400.07%	-	-
Free Cash Flow Margin	-86.92%	-147.18%	-23.51%	-336.64%	-	-
EBITDA	-94.18	-109.04	-51.92	-117.06	-123.68	-81.78
EBITDA Margin	-114.16%	-168.52%	-39.78%	-374.75%	-	-
Depreciation & Amortization	5.67	5.61	5.17	4.55	2.59	1.19
EBIT	-99.85	-114.65	-57.09	-121.62	-126.27	-82.97
EBIT Margin	-121.03%	-177.20%	-43.75%	-389.32%	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).